Piper Sandler Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Iovance Biotherapeutics (IOVA – Research Report), ...
Iovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler
Piper Sandler analyst Joseph Catanzaro lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $7.50 from $10 and keeps a Neutral ...